Is Elevidys Contraindicated for DMD Exon 8 or 9 Deletions?

In the United States, the current FDA prescribing information states that Elevidys (delandistrogene moxeparvovec-rokl) is contraindicated—meaning it should not be used under any circumstances—for individuals with Duchenne muscular dystrophy (DMD) who have any genetic deletion involving exon 8 and/or exon 9 ^[1].

This exclusion is in place because patients with these specific genetic mutations face a significantly increased risk of developing a potentially severe, and in some cases life-threatening, condition called immune-mediated myositis (severe muscle inflammation driven by the immune system) following the gene therapy infusion ^[1].

The Proposed Biological Rationale

An exon is a specific segment of a gene that provides instructions for building proteins. To understand why this immune reaction happens, researchers have proposed a biological explanation based on how the immune system reacts to the therapy ^[1]:

• The Missing Sequences: Children with a deletion in exon 8 or 9 have never naturally produced the specific parts of the dystrophin protein that correspond to those exons ^[1].
• The Gene Therapy: Elevidys works by delivering a shortened version of the dystrophin gene, known as “micro-dystrophin.” This delivered micro-dystrophin contains the protein regions coded by exons 8 and 9 ^[1].
• The Immune Reaction: Because the patient’s body may lack immunological tolerance to these specific protein regions, the immune system can recognize the newly produced micro-dystrophin as a foreign threat. The body may then mount a T-cell response—meaning specialized white blood cells attack the newly treated muscle tissue ^[1].

While this is the leading scientific explanation, the precise mechanism may vary, and not every child with these deletions will necessarily have the exact same immune response. However, the risk is considered too high to safely administer the therapy ^[1].

Clinical Trial Evidence

This safety warning stems from serious adverse events observed in the phase Ib ENDEAVOR clinical trial ^[1]. During the study:

• Two serious cases of immune-mediated myositis occurred in patients receiving Elevidys ^[1].
• Specialized immune tests (T-cell ELISpot testing) detected that the patients’ immune systems were reacting to the specific regions of the micro-dystrophin protein corresponding to exons 8 and 9 in one case, and exon 8 in the other ^[1].
• Computer-based (in-silico) modeling supported these findings by predicting that the patients’ immune cells had a high probability of binding to these specific protein segments ^[1].

While computer modeling is a prediction rather than clinical proof, the combination of trial cases and immune testing led the FDA to establish a strict contraindication for this genetic subgroup to prevent dangerous immune reactions ^[1].

What This Means For Your Child

If your child’s official genetic report confirms a deletion involving exon 8 and/or exon 9, they are not eligible for Elevidys. Because genetic reports can be highly complex, containing reading-frame descriptions and laboratory terminology, do not attempt to interpret the exon wording on your own. Always have a neuromuscular geneticist or genetic counselor confirm whether your child’s specific variant meets the criteria for this contraindication.

Important Note on Ongoing Care:
Being ineligible for Elevidys does not mean your child has no treatment options. This is a specific warning for one therapy. Standard DMD care—including ongoing steroid management, physical therapy, heart and breathing surveillance, and potential eligibility for other clinical trials using different therapies—remains fully available and critical to your child’s health.

Safety Warning for Previously Treated Patients
If your child has already received Elevidys (for example, in a clinical trial) and experiences new or worsening muscle weakness, severe muscle pain, dark urine, trouble swallowing, or breathing difficulty, seek immediate emergency medical evaluation or contact your neuromuscular treating team right away. These can be signs of severe myositis or muscle breakdown and require urgent intervention ^[1][2]. Do not wait for a routine follow-up appointment.